Here Vince describes in detail a new product PEA to help with the issues listed below. There are links in the description to articles you might find useful for further research and reading.

Click here to read 'PEA FACTSHEET'.

BREAKTHROUGH NATURAL SUPPORT FOR:

1. ITCHING CAUSED BY A SENSITIVITY TO ENVIRONMENTAL ALLERGENS

2. JOINT RELIEF

3. COGNITIVE HEALTH

• MICRONISED FOR OPTIMUM POTENCY
• ONLY FORM FORMULATED SPECIFICALLY FOR ANIMALS TO ENSURE MAXIMUM BENEFITS
• NO FILLERS, BINDERS, GLUES OR CHEMICAL ADDITIVES OF ANY KIND.

ITCHY SKIN
SENSITIVITY TO ENVIRONMENTAL ALLERGENS

Click here to read 'How is atopy diagnosed?'

Click here to read 'An Itchy Skin - A Simple Approach.'

Click here to read 'What if my pet is already on medication for Itching?'

Efficacy of ultra-micronized palmitoylethanolamide in canine atopic dermatitis: an open-label multi-centre study

Summary:

66% of dogs benefited from micronised PEA supplementation, in terms of reduced itching and improved quality of life after 8 weeks.

JOINT HEALTH

JOINTS STIFFNESS AND PAIN MANAGEMENT

Click here to read about 'Ultimate Joint Support - How to avoid non-steroidal anti-inflammatories (NSAID's) and Librela.'

Summary:

Supplementation with micronised PEA shows promise for managing chronic pain, including joint pain, in dogs, cats and horses.

Oral Supplementation with Ultramicronised Palmitoylethanolamide for Joint Disease and Lameness Management in Four Jumping Horses: A Case Report

Summary:

BRAIN AND COGNITIVE FUNCTION

Successful and Unsuccessful Brain Aging in Pets

Summary:

In various in vitro and animal models of neurodegenerative conditions and senile dementia, PEA exhibits anti-inflammatory and neuroprotective effects, and supports improved cognitive performance in elderly animals.

PAIN MANAGEMENT

A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis (in humans)

Summary:

The study assessed the safety, tolerability, and efficacy of palmitoylethanolamide (PEA) in 111 adults with mild to moderate knee osteoarthritis. Improvements were seen in all measured outcomes (joint pain, stiffness, and function) using the WOMAC sub-domains, suggesting that PEA is effective in reducing symptoms of knee osteoarthritis and improving quality of life.

(Vince the Vet PEA is human food grade quality.)

Palmitoylethanolamide in the Treatment of Chronic Pain Caused by Different Etiopathogenesis

Summary:

The study on palmitoylethanolamide (PEA) included a total of 610 participants who were suffering from various chronic pain conditions involving nerves, muscles, joints and other parts of the body.